Nova Biomedical Awarded Multi-Year Blood Glucose Meter Agreement from Premier

WALTHAM, Mass. - May 2, 2018 - PRLog -- Nova Biomedical has been awarded a new multi-year group purchasing agreement for glucose meters from Premier. This agreement provides Premier members access to contracts for Nova's StatStrip^® Glucose Hospital Meter System, which measures and corrects for interferences and is the only glucose meter cleared by the U.S. Food and Drug Administration (FDA) for use with critically ill patients.

Effective April 1, 2018, through March, 2021, the new agreement allows Premier members, at their discretion, to take advantage of special, pre-negotiated pricing and terms for StatStrip meters and advanced technology test strips.

"We are pleased that Premier has selected our innovative StatStrip Glucose technology to help them achieve their commitment to superior patient care," said John Britt, Director of Corporate Accounts for Nova. "This agreement allows Premier members access to the only glucose meter that is FDA cleared for use with critically ill patients. Use of any other glucose meter with critically ill patients is considered off-label by the FDA. We look forward to working with Premier and its members to implement StatStrip technology at their hospitals."

StatStrip uses novel glucose test strip technology that measures and corrects for hematocrit and other common interferences such as maltose, galactose, acetaminophen, ascorbic acid, and oxygen, which cause erroneous glucose results. StatStrip's accuracy has been comprehensively evaluated and validated in a study of 1,698 critically ill patients across a broad variety of critical care settings, including intensive care, neonatal intensive care, surgery, emergency, tertiary care, and dialysis, evidencing the importance of this technology breakthrough for bedside glucose testing.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About Nova Biomedical

Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood, point-of-care and critical care analyzers, as well as providing the biotechnology industry with the most advanced instruments for cell culture monitoring. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova's biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova employs over 1,200 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, France, Germany, Great Britain, Italy, Japan, and Taiwan. Certified by the International Organization for Standardization, Nova has manufacturing operations in the U.S., Taiwan, and Brazil. www.novabiomedical.com